Mitchell Machtay MD FACR FASTRO

Radiation Oncology•Hershey, PA

Central Nervous System Cancer, Head & Neck, Thoracic Cancer

Professor, Associate Cancer Center Director and Associate Dean

Join to View Full Profile

500 University DriveHershey, PA 17033
Phone+1 717-531-4477

Education & Training

University of Pennsylvania Health SystemResidency, Radiation Oncology, 1990 - 1993
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1989 - 1990
New York University School of MedicineClass of 1989

Certifications & Licensure

OH State Medical License 2009 - 2026
PA State Medical License 1991 - 2026
NJ State Medical License 1993 - 2011
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Philadelphia Magazine Castle Connolly, 2005-2006, 2009-2010

Clinical Trials

Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Start of enrollment: 1998 Dec 01
Terminated
Phase 2
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 3
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer Start of enrollment: 2005 Mar 01
Unknown status
Phase 2
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer Start of enrollment: 2012 Feb 22
Active, not recruiting
Phase 2
Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning Start of enrollment: 2016 Jul 21
Completed
Not Applicable
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Start of enrollment: 2019 Aug 30
Terminated
Early Phase 1
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC Start of enrollment: 2025 Jun 01
NOT_YET_RECRUITING
EARLY_PHASE1
Roles: Contact, Sponsor-Investigator, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
Feng-Ming Spring Kong, Chen Hu, Jeffrey D Bradley, Mitchell Machtay
Journal of Clinical Oncology. 2025-03-21
Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.
Alireza Mansouri, Ahmad Ozair, Debarati Bhanja, Hannah Wilding, Elad Mashiach
Nature Reviews. Clinical Oncology. 2025-03-19
Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.
Ying Xiao, Stanley Benedict, Yunfeng Cui, Carri Glide-Hurst, Stephen Graves
International Journal of Radiation Oncology, Biology, Physics. 2025-01-22

Journal Articles

Multi-Institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients with Brain Metastases
Simon S Lo, Wenyin Shi, Kristin J Redmond, Mitchell Machtay, JAMA Oncology

Other

Treatment of early (stage I and II) head and neck cancer: The larynx
Machtay M, Koch WM
http://www.uptodate.com/contents/treatment-of-early-stage-i-and-ii-head-and-neck-cancer-the-larynx
UpToDate, Wolters Kluwer Health - 2013-02-05

Press Mentions

Postoperative RT plus Cetuximab Showed Mixed Results in Head and Neck Cancer TrialJanuary 30th, 2025
Combination of Radiotherapy and Cetuximab Show Promise in Enhancing Outcomes for Select Head and Neck Cancer Patients Post-SurgeryJanuary 24th, 2025
Mixed Results with Midtreatment PET-Adapted RT in Stage III NSCLCJanuary 20th, 2025
Join now to see all